Nasdaq:US$16.32 (-0.56) | HKEX:HK$25.60 (-1.00) | AIM:£2.60 (-0.1)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2016-12-05

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis

Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5, Yi-Long Wu1

1Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou/China, 2Zhongshan Hospital, Shanghai Fudan University, Shanghai/China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing/China, 4307 Hospital, PLA, Beijing/China, 5Hutchison MediPharma Ltd, Shanghai/China

 

Conference: 17th World Conference on Lung Cancer
Abstract: #4253
1st Session: JCES01 Joint IASLC–Chinese Society for Clinical Oncology /
Chinese Alliance Against Lung Cancer Session (ID 413)
Date & Time: Sunday, December 4, 2016 (10:30 AM – 11:30 AM)
2nd Session: 07. Advanced NSCLC
P2.03b – Poster Session with Presenters Present (ID 465)
Date & Time: Tuesday, December 6, 2016 (2:30 PM – 3:45 PM)